Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Rises By 28.6%

Gain Therapeutics, Inc. (NASDAQ:GANX) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totaling 2,666,410 shares, a growth of 28.6% from the December 15th total of 2,073,310 shares. Based on an average daily trading volume, of 2,698,186 shares, the days-to-cover ratio is presently 1.0 days. Currently, 7.5% of the company’s stock are sold short. Currently, 7.5% of the company’s stock are sold short. Based on an average daily trading volume, of 2,698,186 shares, the days-to-cover ratio is presently 1.0 days.

Gain Therapeutics Stock Performance

GANX stock traded down $0.07 during trading on Friday, reaching $1.81. 1,842,540 shares of the company’s stock were exchanged, compared to its average volume of 1,711,706. Gain Therapeutics has a 1-year low of $1.41 and a 1-year high of $4.34. The firm has a market cap of $69.62 million, a PE ratio of -2.97 and a beta of 0.06. The company’s fifty day moving average price is $3.05 and its 200-day moving average price is $2.21. The company has a quick ratio of 2.52, a current ratio of 2.52 and a debt-to-equity ratio of 0.05.

Gain Therapeutics (NASDAQ:GANX) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.15) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.15). On average, research analysts expect that Gain Therapeutics will post -1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

GANX has been the subject of several research analyst reports. Roth Capital reissued a “buy” rating and issued a $10.00 target price on shares of Gain Therapeutics in a research report on Friday, December 19th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Gain Therapeutics in a research note on Monday, December 29th. BTIG Research restated a “buy” rating and issued a $9.00 price target on shares of Gain Therapeutics in a research report on Wednesday, October 15th. Maxim Group lifted their target price on Gain Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of Gain Therapeutics in a research report on Friday, December 19th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.67.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in GANX. Geode Capital Management LLC boosted its stake in Gain Therapeutics by 2.9% during the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock valued at $523,000 after purchasing an additional 8,251 shares in the last quarter. Marshall Wace LLP lifted its holdings in shares of Gain Therapeutics by 41.0% in the second quarter. Marshall Wace LLP now owns 276,433 shares of the company’s stock valued at $498,000 after buying an additional 80,407 shares during the period. Virtu Financial LLC boosted its stake in Gain Therapeutics by 126.9% during the third quarter. Virtu Financial LLC now owns 54,008 shares of the company’s stock valued at $96,000 after buying an additional 30,207 shares in the last quarter. Squarepoint Ops LLC bought a new position in Gain Therapeutics during the third quarter valued at about $68,000. Finally, Benedict Financial Advisors Inc. grew its holdings in Gain Therapeutics by 55.6% during the third quarter. Benedict Financial Advisors Inc. now owns 35,000 shares of the company’s stock worth $62,000 after acquiring an additional 12,500 shares during the period. Institutional investors and hedge funds own 11.97% of the company’s stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.